Business Context and Reporting Period
This Form 8-K filing by Surgery Partners, Inc. (SGRY) reports on events occurring on June 6, 2025, specifically the conclusion of the Company's 2025 Annual Meeting of Stockholders. The filing details the outcomes of shareholder votes regarding director elections, executive compensation, incentive plans, and the ratification of the independent auditor.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder actions. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial statement line items.
Material Changes and Voting Results
The filing documents the following material shareholder actions and voting outcomes based on 128,192,739 shares outstanding as of the April 8, 2025 record date:
- Director Elections (Proposal 1): Stockholders re-elected all three Class I director nominees (John A. Deane, Teresa DeLuca, M.D., and Wayne S. DeVeydt) to serve until the 2028 annual meeting.
- Executive Compensation (Proposal 2): Stockholders approved the advisory vote on executive compensation. Approximately 83.4% of votes cast were in favor (96,577,058 For vs. 19,241,638 Against).
- Incentive Plan Approval (Proposal 3): Stockholders approved the 2025 Omnibus Incentive Plan. Approximately 87.9% of votes cast were in favor (101,740,477 For vs. 13,957,369 Against).
- Auditor Ratification (Proposal 4): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2025. The vote was overwhelmingly in favor (122,065,302 For vs. 30,124 Against).
Guidance, Outlook, and Risks
This filing contains no management guidance, financial outlook, or discussion of risks and contingencies. The document focuses exclusively on the procedural results of the Annual Meeting and the approval of the 2025 Omnibus Incentive Plan, the text of which is filed as an exhibit.
Key Facts for Investor Verification
- Verify the specific terms and share limits of the newly approved 2025 Omnibus Incentive Plan in the referenced Exhibit 10.
- Note the level of shareholder dissent on the executive compensation advisory vote, where approximately 16.6% of votes cast were against the proposal.
- Confirm the tenure of the re-elected Class I directors, which extends through the 2028 annual meeting.
- Review the Definitive Proxy Statement filed on April 24, 2025, for detailed descriptions of the incentive plan features incorporated by reference.